Goat Polyclonal ACADM/MCAD antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human ACADM aa 400 to C-terminus.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 0.01000-0.10000 µg/mL | Notes A 1 hour primary incubation is recommended for this product. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 3.75 µg/mL | Notes - |
Select an associated product type
Medium-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation, an aerobic process breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed:1970566, PubMed:21237683, PubMed:2251268, PubMed:8823175). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (PubMed:2251268). Electron transfer flavoprotein (ETF) is the electron acceptor that transfers electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase) (PubMed:15159392, PubMed:25416781). Among the different mitochondrial acyl-CoA dehydrogenases, medium-chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 6 to 12 carbons long primary chains (PubMed:1970566, PubMed:21237683, PubMed:2251268, PubMed:8823175).
MCAD, Medium chain acyl-CoA dehydrogenase, MCADH, ACADM
Goat Polyclonal ACADM/MCAD antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human ACADM aa 400 to C-terminus.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
ACADM also known as MCAD (medium-chain acyl-CoA dehydrogenase) is an enzyme that plays a significant role in fatty acid metabolism. It weighs approximately 44 kDa and expresses mainly in the liver heart and skeletal muscles. Functions of MCAD involve catalyzing the initial step in the mitochondrial fatty acid β-oxidation spiral specifically for the medium-chain fatty acids. This enzyme helps in the conversion of fatty acyl-CoA to trans-enoyl-CoA through dehydrogenation.
The enzyme facilitates energy production by breaking down medium-chain fatty acids within mitochondria. MCAD operates as a homotetramer complex where each subunit significantly contributes to its overall function. Such enzymatic activity is important for providing energy particularly when glycogen stores are low. Its efficient operation during fasting states indicates its importance in metabolic homeostasis.
Medium-chain acyl-CoA dehydrogenase (MCAD) is integral to the mitochondrial fatty acid beta-oxidation pathway. This pathway is a primary route for fatty acid catabolism ultimately leading to energy production in the form of ATP. MCAD's activity also relates to other fatty acid oxidation enzymes like VLCAD (very-long-chain acyl-CoA dehydrogenase) and SCAD (short-chain acyl-CoA dehydrogenase) which operate on different chain-length fatty acids cooperating to maintain energy balance.
MCAD deficiency is a common metabolic disorder that impairs the normal breakdown of fatty acids. This condition results in the accumulation of fatty acid intermediates leading to hypoketotic hypoglycemia during fasting periods. Individuals with MCAD deficiency may experience lethargy vomiting and seizures. The disorder connects with other enzymes such as LCHAD (long-chain 3-hydroxyacyl-CoA dehydrogenase) involved in similar pathways and deficiencies can result in related metabolic dysfunctions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab13677 staining (0.05μg/ml) of Human Heart lysate (RIPA buffer, 35μg total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence.
Primary incubated for 1 hour.
All lanes: Western blot - Anti-ACADM/MCAD antibody (ab13677) at 0.05 µg/mL
All lanes: Human heart lysates at 35 µg
Developed using the ECL technique.
Predicted band size: 47 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com